Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Center for Human Genetics, |
RCV000680513 | SCV000807898 | likely benign | Connective tissue disorder | 2018-06-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002232815 | SCV001372608 | likely benign | Ehlers-Danlos syndrome, classic type, 1 | 2023-12-27 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001838092 | SCV002098185 | uncertain significance | not provided | 2022-02-15 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function |
Ambry Genetics | RCV002458191 | SCV002616712 | uncertain significance | Familial thoracic aortic aneurysm and aortic dissection | 2024-01-31 | criteria provided, single submitter | clinical testing | The p.N1189K variant (also known as c.3567C>A), located in coding exon 50 of the COL5A2 gene, results from a C to A substitution at nucleotide position 3567. The asparagine at codon 1189 is replaced by lysine, an amino acid with similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this alteration remains unclear. |